{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-144952","form_type":"8-K/A","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.986226+00:00","generated_at":"2026-06-15T01:33:13.255458+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cytek acquired flow cytometry business with $43.1M revenue, $4.4M loss in 2022","bullets":["Purchase price was $46.5M less $1.6M working capital adjustments and transaction fees.","Net assets acquired: $44.1M assets, $5.7M liabilities, net $38.4M as of Dec 31, 2022.","FY2022 revenue: $43.1M (product $32.3M, service $10.8M); direct expenses $47.5M.","Abbreviated financials exclude corporate overhead, taxes, interest; not a standalone entity.","Acquired brands include Amnis, CellStream, Guava, Muse; closing occurred Feb 28, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-144952","json":"https://secwatch.observer/filing/0001193125-23-144952.json","markdown":"https://secwatch.observer/filing/0001193125-23-144952.md","text":"https://secwatch.observer/filing/0001193125-23-144952.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523144952/0001193125-23-144952-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523144952/d467217d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:33:13.255458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}